{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T22:23:29Z","timestamp":1649197409482},"reference-count":1,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/naika.103.645","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T22:07:24Z","timestamp":1425938844000},"page":"645-649","source":"Crossref","is-referenced-by-count":0,"title":["5. Diagnosis and Treatment of Water Disorder"],"prefix":"10.2169","volume":"103","author":[{"given":"Yutaka","family":"Oiso","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"5) Schrier RW, et al: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. New Eng J Med 355: 2099-2112, 2006.","DOI":"10.1056\/NEJMoa065181"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["5\uff0e\u6c34\u4ee3\u8b1d\u75be\u60a3\u306e\u8a3a\u65ad\u3068\u6cbb\u7642"],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T20:20:42Z","timestamp":1566418842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/3\/103_645\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":1,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.103.645","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}